tetano
Editor, Senior Moderator
J Med Virol
. 2022 Jun 15.
doi: 10.1002/jmv.27937. Online ahead of print.
Human seasonal coronavirus neutralisation and COVID-19 severity
David A Wells[SUP] 1 2 [/SUP], Diego Cantoni[SUP] 3 [/SUP], Martin Mayora-Neto[SUP] 3 [/SUP], Cecilia Di Genova[SUP] 3 [/SUP], Alexander Sampson[SUP] 1 [/SUP], Matteo Ferrari[SUP] 1 2 [/SUP], George Carnell[SUP] 1 [/SUP], Angalee Nadesalingam[SUP] 1 [/SUP], Peter Smith[SUP] 1 [/SUP], Andrew Chan[SUP] 1 [/SUP], Gianmarco Raddi[SUP] 4 [/SUP], Javier Castillo-Olivares[SUP] 1 [/SUP], Helen Baxendale[SUP] 4 [/SUP], Nigel Temperton[SUP] 3 [/SUP], Jonathan L Heeney[SUP] 1 2 [/SUP]
Affiliations
Abstract
The virus SARS-CoV-2, responsible for the global COVID-19 pandemic, spread rapidly around the world causing high morbidity and mortality. However, there are four known, endemic seasonal coronaviruses in humans (HCoVs) and whether antibodies for these HCoVs play a role in severity of COVID-19 disease has generated a lot of interest. Of these seasonal viruses NL63 is of particular interest as it uses the same cell entry receptor as SARS-CoV-2. We use functional, neutralising assays to investigate cross reactive antibodies and their relationship with COVID-19 severity. We analysed neutralisation of SARS-CoV-2, NL63, HKU1, and 229E in 38 COVID-19 patients and 62 healthcare workers, and a further 182 samples to specifically study the relationship between SARS-CoV-2 and NL63.We found that although HCoV neutralisation was very common there was little evidence that these antibodies neutralised SARS-CoV-2. Despite no evidence in cross neutralisation, levels of NL63 neutralising antibodies become elevated after exposure to SARS-CoV-2 through infection or following vaccination. This article is protected by copyright. All rights reserved.
Keywords: Endemic infection; Epidemiology; Immune responses; Neutralization; SARS coronavirus; Virus classification.
. 2022 Jun 15.
doi: 10.1002/jmv.27937. Online ahead of print.
Human seasonal coronavirus neutralisation and COVID-19 severity
David A Wells[SUP] 1 2 [/SUP], Diego Cantoni[SUP] 3 [/SUP], Martin Mayora-Neto[SUP] 3 [/SUP], Cecilia Di Genova[SUP] 3 [/SUP], Alexander Sampson[SUP] 1 [/SUP], Matteo Ferrari[SUP] 1 2 [/SUP], George Carnell[SUP] 1 [/SUP], Angalee Nadesalingam[SUP] 1 [/SUP], Peter Smith[SUP] 1 [/SUP], Andrew Chan[SUP] 1 [/SUP], Gianmarco Raddi[SUP] 4 [/SUP], Javier Castillo-Olivares[SUP] 1 [/SUP], Helen Baxendale[SUP] 4 [/SUP], Nigel Temperton[SUP] 3 [/SUP], Jonathan L Heeney[SUP] 1 2 [/SUP]
Affiliations
- PMID: 35705514
- DOI: 10.1002/jmv.27937
Abstract
The virus SARS-CoV-2, responsible for the global COVID-19 pandemic, spread rapidly around the world causing high morbidity and mortality. However, there are four known, endemic seasonal coronaviruses in humans (HCoVs) and whether antibodies for these HCoVs play a role in severity of COVID-19 disease has generated a lot of interest. Of these seasonal viruses NL63 is of particular interest as it uses the same cell entry receptor as SARS-CoV-2. We use functional, neutralising assays to investigate cross reactive antibodies and their relationship with COVID-19 severity. We analysed neutralisation of SARS-CoV-2, NL63, HKU1, and 229E in 38 COVID-19 patients and 62 healthcare workers, and a further 182 samples to specifically study the relationship between SARS-CoV-2 and NL63.We found that although HCoV neutralisation was very common there was little evidence that these antibodies neutralised SARS-CoV-2. Despite no evidence in cross neutralisation, levels of NL63 neutralising antibodies become elevated after exposure to SARS-CoV-2 through infection or following vaccination. This article is protected by copyright. All rights reserved.
Keywords: Endemic infection; Epidemiology; Immune responses; Neutralization; SARS coronavirus; Virus classification.